COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 14 of 40 for:    Terbinafine

TDT 067 Open Label Multi-Dose Onychomycosis Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01790165
Recruitment Status : Completed
First Posted : February 13, 2013
Last Update Posted : February 13, 2013
Information provided by (Responsible Party):
Celtic Pharma Development Services

Brief Summary:

The aim of this study is to establish a clinical bridge to Lamisil® tablets by conducting a clinical pharmacokinetic (PK) study comparing the systemic exposure of a Lamisil® tablet with that of with TDT 067 under maximal use conditions.

Under maximal use conditions in onychomycotic subjects, the aim is to confirm that there are significantly lower plasma levels of terbinafine and its major metabolites after a topical administration of TDT 067 for 28 days in comparison with a single oral 250 mg Lamisil® tablet.

Condition or disease Intervention/treatment Phase
Onychomycosis Drug: TDT067 and Lamisil Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Screening
Official Title: A Phase II Open Label Multiple-Dose Study of the Safety and Pharmacokinetics of TDT 067 Under Conditions of Maximal Use in Subjects With Distal Subungual Onychomycosis of the Toenails
Study Start Date : December 2009
Actual Primary Completion Date : January 2010
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TDT067
Active treatment
Drug: TDT067 and Lamisil
Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
Other Name: Lamisil

Placebo Comparator: Placebo

Primary Outcome Measures :
  1. PK [ Time Frame: 35 days ]
    Cmax, Tmax, AUC0-12, AUC0-24, Cmax Ratio (day 28/day 35) were evaluated

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be between 18 and 65 years of age inclusive, of any race, and of either sex.
  • Male subjects only: Male subjects must use a reliable form of contraception during their participation in the trial and for 3 months after their last dose of study drug.
  • Female subjects only: Either of non-childbearing potential (i.e. either surgically sterilized or post menopausal) or must be using adequate contraception, have a negative pregnancy test prior to start of dosing, and must agree to continue to use this method of contraception until 3 months after the last dose. Acceptable contraceptive methods are oral contraceptive, IUD, or diaphragm with spermicide (unless anatomically sterile).
  • Subjects must be in good general health as confirmed by a medical history and physical examination.
  • Subjects must have 2 big toes with nails that have the potential to be clipped to provide nail samples.
  • Subjects must have clinically diagnosed distal subungual onychomycosis of the toenails; at least 5 nails in total must present with onychomycotic signs (onycholysis, subungual hyperkeratosis) including extensive involvement (≥50%) of both large nails and mycological confirmation (positive KOH microscopy) from 1 of the large nails.
  • Subject must sign a statement of informed consent.
  • Subjects must be able to understand the requirements of the study, abide by the restriction, and return for all of the required examinations

Exclusion Criteria:

  • Subjects lacking any toes.
  • Subjects with known hypersensitivity to terbinafine or any of the excipients in the TDT 067.
  • Subjects with symptomatic tinea pedis requiring treatment.
  • Subjects with any medical, neurological, or psychiatric conditions that in the opinion of the Investigator would make the subject unsuitable for enrollment onto the study.
  • Subjects with chronic or active liver disease, as well as subjects with elevated liver function tests above normal for the testing laboratory.
  • Subjects with renal impairment (creatinine clearance ≤50 mL/min).
  • Subjects who have received terbinafine tablets within 12 months or topical terbinafine (cream, solution/spray, or gel) within 6 months prior to screening visit; subjects who have received other oral antifungals within 4 months or other topical antifungals within 1 month.
  • Subjects who have participated within the previous 3 months in a clinical trial for the systemic or topical treatment of onychomycosis.
  • Subjects being treated with rifampin or cimetidine.
  • Subjects being treated with an investigational drug within 1 month prior to study start.
  • Subjects with psoriasis or history of psoriasis.
  • Subjects with nail dystrophy or other nail abnormalities other than onychomycosis.
  • Subjects with serious concurrent disease that might prevent completion of the trial.
  • Subjects who are pregnant (confirmed by pregnancy test) or who plan to become pregnant within the study timeframe or who are nursing.
  • Subjects who cannot read, understand, or sign the informed consent form or the instructions for applying and removing the study formulations.
  • Subjects who cannot apply the product to their toenails.
  • Subjects who do not wish to provide nail clippings.
  • Subjects who cannot or will not provide adequate blood and urine samples.
  • Subjects using any nail polish products or other nail cosmetic products on any of the toenails designated for treatment within 7 days prior to the start of treatment and who are unwilling to discontinue use of these products for the duration of this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01790165

Sponsors and Collaborators
Celtic Pharma Development Services
Layout table for investigator information
Principal Investigator: Eduardo Tschen, MD Academic Dermatology Assoc
Layout table for additonal information
Responsible Party: Celtic Pharma Development Services Identifier: NCT01790165    
Other Study ID Numbers: CL-067-II-02
First Posted: February 13, 2013    Key Record Dates
Last Update Posted: February 13, 2013
Last Verified: February 2013
Keywords provided by Celtic Pharma Development Services:
Open Label
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Infectious
Nail Diseases
Skin Diseases
Antifungal Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action